Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model.

Lu G, Pine P, Leeds JM, DeGuzman F, Pratikhya P, Lin J, Malinowski J, Hollenbach SJ, Curnutte JT, Conley PB.

PLoS One. 2018 Mar 28;13(3):e0195122. doi: 10.1371/journal.pone.0195122. eCollection 2018.

2.

Cell-based reference samples designed with specific differences in microRNA biomarkers.

Pine PS, Lund SP, Stass SA, Kukuruga D, Jiang F, Sorbara L, Srivastava S, Salit M.

BMC Biotechnol. 2018 Mar 20;18(1):17. doi: 10.1186/s12896-018-0423-4.

3.

Summarizing performance for genome scale measurement of miRNA: reference samples and metrics.

Pine PS, Lund SP, Parsons JR, Vang LK, Mahabal AA, Cinquini L, Kelly SC, Kincaid H, Crichton DJ, Spira A, Liu G, Gower AC, Pass HI, Goparaju C, Dubinett SM, Krysan K, Stass SA, Kukuruga D, Van Keuren-Jensen K, Courtright-Lim A, Thompson KL, Rosenzweig BA, Sorbara L, Srivastava S, Salit ML.

BMC Genomics. 2018 Mar 6;19(1):180. doi: 10.1186/s12864-018-4496-1.

4.

Two approaches for estimating the lower limit of quantitation (LLOQ) of microRNA levels assayed as exploratory biomarkers by RT-qPCR.

Wolfinger RD, Beedanagari S, Boitier E, Chen T, Couttet P, Ellinger-Ziegelbauer H, Guillemain G, Mariet C, Mouritzen P, O'Lone R, Pine PS, Sharapova T, Yan J, Yuen PS, Thompson KL.

BMC Biotechnol. 2018 Feb 2;18(1):6. doi: 10.1186/s12896-018-0415-4.

5.

Absolute Measurement of Cardiac Injury-Induced microRNAs in Biofluids across Multiple Test Sites.

Thompson KL, Boitier E, Chen T, Couttet P, Ellinger-Ziegelbauer H, Goetschy M, Guillemain G, Kanki M, Kelsall J, Mariet C, de La Moureyre-Spire C, Mouritzen P, Nassirpour R, O'Lone R, Pine PS, Rosenzweig BA, Sharapova T, Smith A, Uchiyama H, Yan J, Yuen PS, Wolfinger R.

Toxicol Sci. 2016 Nov;154(1):115-125. Epub 2016 Sep 7.

PMID:
27605421
6.

External RNA Controls Consortium Beta Version Update.

Lee H, Pine PS, McDaniel J, Salit M, Oliver B.

J Genomics. 2016 Jul 26;4:19-22. doi: 10.7150/jgen.16082. eCollection 2016.

7.

Evaluation of the External RNA Controls Consortium (ERCC) reference material using a modified Latin square design.

Pine PS, Munro SA, Parsons JR, McDaniel J, Lucas AB, Lozach J, Myers TG, Su Q, Jacobs-Helber SM, Salit M.

BMC Biotechnol. 2016 Jun 24;16(1):54. doi: 10.1186/s12896-016-0281-x.

8.

An international comparability study on quantification of mRNA gene expression ratios: CCQM-P103.1.

Devonshire AS, Sanders R, Whale AS, Nixon GJ, Cowen S, Ellison SL, Parkes H, Pine PS, Salit M, McDaniel J, Munro S, Lund S, Matsukura S, Sekiguchi Y, Kawaharasaki M, Granjeiro JM, Falagan-Lotsch P, Saraiva AM, Couto P, Yang I, Kwon H, Park SR, Demšar T, Žel J, Blejec A, Milavec M, Dong L, Zhang L, Sui Z, Wang J, Viroonudomphol D, Prawettongsopon C, Partis L, Baoutina A, Emslie K, Takatsu A, Akyurek S, Akgoz M, Vonsky M, Konopelko LA, Cundapi EM, Urquiza MP, Huggett JF, Foy CA.

Biomol Detect Quantif. 2016 Jun 6;8:15-28. doi: 10.1016/j.bdq.2016.05.003. eCollection 2016 Jun.

9.

Using mixtures of biological samples as process controls for RNA-sequencing experiments.

Parsons J, Munro S, Pine PS, McDaniel J, Mehaffey M, Salit M.

BMC Genomics. 2015 Sep 17;16:708. doi: 10.1186/s12864-015-1912-7.

10.

Assessing technical performance in differential gene expression experiments with external spike-in RNA control ratio mixtures.

Munro SA, Lund SP, Pine PS, Binder H, Clevert DA, Conesa A, Dopazo J, Fasold M, Hochreiter S, Hong H, Jafari N, Kreil DP, Łabaj PP, Li S, Liao Y, Lin SM, Meehan J, Mason CE, Santoyo-Lopez J, Setterquist RA, Shi L, Shi W, Smyth GK, Stralis-Pavese N, Su Z, Tong W, Wang C, Wang J, Xu J, Ye Z, Yang Y, Yu Y, Salit M.

Nat Commun. 2014 Sep 25;5:5125. doi: 10.1038/ncomms6125.

PMID:
25254650
11.

Ontology analysis of global gene expression differences of human bone marrow stromal cells cultured on 3D scaffolds or 2D films.

Baker BA, Pine PS, Chatterjee K, Kumar G, Lin NJ, McDaniel JH, Salit ML, Simon CG Jr.

Biomaterials. 2014 Aug;35(25):6716-26. doi: 10.1016/j.biomaterials.2014.04.075. Epub 2014 May 17.

PMID:
24840613
12.

Janus kinase 1/3 signaling pathways are key initiators of TH2 differentiation and lung allergic responses.

Ashino S, Takeda K, Li H, Taylor V, Joetham A, Pine PR, Gelfand EW.

J Allergy Clin Immunol. 2014 Apr;133(4):1162-74. doi: 10.1016/j.jaci.2013.10.036. Epub 2013 Dec 22.

13.

Inhibition of Syk activity by R788 in platelets prevents remote lung tissue damage after mesenteric ischemia-reperfusion injury.

Lapchak PH, Kannan L, Rani P, Pamuk ON, Ioannou A, Dalle Lucca JJ, Pine P, Tsokos GC.

Am J Physiol Gastrointest Liver Physiol. 2012 Jun 15;302(12):G1416-22. doi: 10.1152/ajpgi.00026.2012. Epub 2012 Apr 5.

14.

The determination of stem cell fate by 3D scaffold structures through the control of cell shape.

Kumar G, Tison CK, Chatterjee K, Pine PS, McDaniel JH, Salit ML, Young MF, Simon CG Jr.

Biomaterials. 2011 Dec;32(35):9188-96. doi: 10.1016/j.biomaterials.2011.08.054. Epub 2011 Sep 3.

15.

R723, a selective JAK2 inhibitor, effectively treats JAK2V617F-induced murine myeloproliferative neoplasm.

Shide K, Kameda T, Markovtsov V, Shimoda HK, Tonkin E, Fang S, Liu C, Gelman M, Lang W, Romero J, McLaughlin J, Bhamidipati S, Clough J, Low C, Reitsma A, Siu S, Pine P, Park G, Torneros A, Duan M, Singh R, Payan DG, Matsunaga T, Hitoshi Y, Shimoda K.

Blood. 2011 Jun 23;117(25):6866-75. doi: 10.1182/blood-2010-01-262535. Epub 2011 Apr 29.

PMID:
21531978
16.
17.

Spleen tyrosine kinase inhibition prevents tissue damage after ischemia-reperfusion.

Pamuk ON, Lapchak PH, Rani P, Pine P, Dalle Lucca JJ, Tsokos GC.

Am J Physiol Gastrointest Liver Physiol. 2010 Aug;299(2):G391-9. doi: 10.1152/ajpgi.00198.2010. Epub 2010 Jun 3.

18.

Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupus-prone mice.

Deng GM, Liu L, Bahjat FR, Pine PR, Tsokos GC.

Arthritis Rheum. 2010 Jul;62(7):2086-92. doi: 10.1002/art.27452.

19.

R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.

Holland SJ, Pan A, Franci C, Hu Y, Chang B, Li W, Duan M, Torneros A, Yu J, Heckrodt TJ, Zhang J, Ding P, Apatira A, Chua J, Brandt R, Pine P, Goff D, Singh R, Payan DG, Hitoshi Y.

Cancer Res. 2010 Feb 15;70(4):1544-54. doi: 10.1158/0008-5472.CAN-09-2997. Epub 2010 Feb 9.

20.

Overview of laser microbeam applications as related to antibody targeting.

Pine PS.

Methods Mol Biol. 2010;588:203-17. doi: 10.1007/978-1-59745-324-0_22. Review.

PMID:
20012833
21.

Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen.

McLaughlin J, Markovtsov V, Li H, Wong S, Gelman M, Zhu Y, Franci C, Lang D, Pali E, Lasaga J, Low C, Zhao F, Chang B, Gururaja TL, Xu W, Baluom M, Sweeny D, Carroll D, Sran A, Thota S, Parmer M, Romane A, Clemens G, Grossbard E, Qu K, Jenkins Y, Kinoshita T, Taylor V, Holland SJ, Argade A, Singh R, Pine P, Payan DG, Hitoshi Y.

J Cancer Res Clin Oncol. 2010 Jan;136(1):99-113. doi: 10.1007/s00432-009-0641-1.

PMID:
19609559
22.

JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice.

Chang BY, Zhao F, He X, Ren H, Braselmann S, Taylor V, Wicks J, Payan DG, Grossbard EB, Pine PR, Bullard DC.

J Immunol. 2009 Aug 1;183(3):2183-92. doi: 10.4049/jimmunol.0804063. Epub 2009 Jul 13.

23.

Use of diagnostic accuracy as a metric for evaluating laboratory proficiency with microarray assays using mixed-tissue RNA reference samples.

Pine PS, Boedigheimer M, Rosenzweig BA, Turpaz Y, He YD, Delenstarr G, Ganter B, Jarnagin K, Jones WD, Reid LH, Thompson KL.

Pharmacogenomics. 2008 Nov;9(11):1753-63. doi: 10.2217/14622416.9.11.1753.

24.

Differential expression and molecular associations of Syk in systemic lupus erythematosus T cells.

Krishnan S, Juang YT, Chowdhury B, Magilavy A, Fisher CU, Nguyen H, Nambiar MP, Kyttaris V, Weinstein A, Bahjat R, Pine P, Rus V, Tsokos GC.

J Immunol. 2008 Dec 1;181(11):8145-52.

25.

Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target.

Young RM, Hardy IR, Clarke RL, Lundy N, Pine P, Turner BC, Potter TA, Refaeli Y.

Blood. 2009 Mar 12;113(11):2508-16. doi: 10.1182/blood-2008-05-158618. Epub 2008 Nov 3.

26.

Comparison of the diagnostic performance of human whole genome microarrays using mixed-tissue RNA reference samples.

Thompson KL, Pine PS.

Toxicol Lett. 2009 Apr 10;186(1):58-61. doi: 10.1016/j.toxlet.2008.08.018. Epub 2008 Sep 7.

PMID:
18822358
27.

Assessment of repeated microarray experiments using mixed tissue RNA reference samples.

Mongan MA, Higgins M, Pine PS, Afshari C, Hamadeh H.

Biotechniques. 2008 Sep;45(3):283-92. doi: 10.2144/000112914. Erratum in: Biotechniques. 2008 Dec;45(6):607. Mongan, Ann [corrected to Mongan, M Ann]; Pine, Scott [corrected to Pine, P Scott].

28.

An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus.

Bahjat FR, Pine PR, Reitsma A, Cassafer G, Baluom M, Grillo S, Chang B, Zhao FF, Payan DG, Grossbard EB, Daikh DI.

Arthritis Rheum. 2008 May;58(5):1433-44. doi: 10.1002/art.23428.

29.
30.

Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor.

Pine PR, Chang B, Schoettler N, Banquerigo ML, Wang S, Lau A, Zhao F, Grossbard EB, Payan DG, Brahn E.

Clin Immunol. 2007 Sep;124(3):244-57. Epub 2007 May 29.

PMID:
17537677
31.
32.

Improvement in the reproducibility and accuracy of DNA microarray quantification by optimizing hybridization conditions.

Han T, Melvin CD, Shi L, Branham WS, Moland CL, Pine PS, Thompson KL, Fuscoe JC.

BMC Bioinformatics. 2006 Sep 6;7 Suppl 2:S17.

33.

The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements.

MAQC Consortium, Shi L, Reid LH, Jones WD, Shippy R, Warrington JA, Baker SC, Collins PJ, de Longueville F, Kawasaki ES, Lee KY, Luo Y, Sun YA, Willey JC, Setterquist RA, Fischer GM, Tong W, Dragan YP, Dix DJ, Frueh FW, Goodsaid FM, Herman D, Jensen RV, Johnson CD, Lobenhofer EK, Puri RK, Schrf U, Thierry-Mieg J, Wang C, Wilson M, Wolber PK, Zhang L, Amur S, Bao W, Barbacioru CC, Lucas AB, Bertholet V, Boysen C, Bromley B, Brown D, Brunner A, Canales R, Cao XM, Cebula TA, Chen JJ, Cheng J, Chu TM, Chudin E, Corson J, Corton JC, Croner LJ, Davies C, Davison TS, Delenstarr G, Deng X, Dorris D, Eklund AC, Fan XH, Fang H, Fulmer-Smentek S, Fuscoe JC, Gallagher K, Ge W, Guo L, Guo X, Hager J, Haje PK, Han J, Han T, Harbottle HC, Harris SC, Hatchwell E, Hauser CA, Hester S, Hong H, Hurban P, Jackson SA, Ji H, Knight CR, Kuo WP, LeClerc JE, Levy S, Li QZ, Liu C, Liu Y, Lombardi MJ, Ma Y, Magnuson SR, Maqsodi B, McDaniel T, Mei N, Myklebost O, Ning B, Novoradovskaya N, Orr MS, Osborn TW, Papallo A, Patterson TA, Perkins RG, Peters EH, Peterson R, Philips KL, Pine PS, Pusztai L, Qian F, Ren H, Rosen M, Rosenzweig BA, Samaha RR, Schena M, Schroth GP, Shchegrova S, Smith DD, Staedtler F, Su Z, Sun H, Szallasi Z, Tezak Z, Thierry-Mieg D, Thompson KL, Tikhonova I, Turpaz Y, Vallanat B, Van C, Walker SJ, Wang SJ, Wang Y, Wolfinger R, Wong A, Wu J, Xiao C, Xie Q, Xu J, Yang W, Zhang L, Zhong S, Zong Y, Slikker W Jr.

Nat Biotechnol. 2006 Sep;24(9):1151-61.

34.

Using RNA sample titrations to assess microarray platform performance and normalization techniques.

Shippy R, Fulmer-Smentek S, Jensen RV, Jones WD, Wolber PK, Johnson CD, Pine PS, Boysen C, Guo X, Chudin E, Sun YA, Willey JC, Thierry-Mieg J, Thierry-Mieg D, Setterquist RA, Wilson M, Lucas AB, Novoradovskaya N, Papallo A, Turpaz Y, Baker SC, Warrington JA, Shi L, Herman D.

Nat Biotechnol. 2006 Sep;24(9):1123-31.

35.

R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.

Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M, Qu K, Herlaar E, Lau A, Young C, Wong BR, Lovell S, Sun T, Park G, Argade A, Jurcevic S, Pine P, Singh R, Grossbard EB, Payan DG, Masuda ES.

J Pharmacol Exp Ther. 2006 Dec;319(3):998-1008. Epub 2006 Aug 31. Erratum in: J Pharmacol Exp Ther. 2013 May;345(2):326.

PMID:
16946104
36.

Workgroup report: Review of genomics data based on experience with mock submissions--view of the CDER Pharmacology Toxicology Nonclinical Pharmacogenomics Subcommittee.

Leighton JK, Brown P, Ellis A, Harlow P, Harrouk W, Pine PS, Robison T, Rosario L, Thompson K.

Environ Health Perspect. 2006 Apr;114(4):573-8. Review.

37.

A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes.

Cha HS, Boyle DL, Inoue T, Schoot R, Tak PP, Pine P, Firestein GS.

J Pharmacol Exp Ther. 2006 May;317(2):571-8. Epub 2006 Feb 1.

PMID:
16452391
38.

Use of a mixed tissue RNA design for performance assessments on multiple microarray formats.

Thompson KL, Rosenzweig BA, Pine PS, Retief J, Turpaz Y, Afshari CA, Hamadeh HK, Damore MA, Boedigheimer M, Blomme E, Ciurlionis R, Waring JF, Fuscoe JC, Paules R, Tucker CJ, Fare T, Coffey EM, He Y, Collins PJ, Jarnagin K, Fujimoto S, Ganter B, Kiser G, Kaysser-Kranich T, Sina J, Sistare FD.

Nucleic Acids Res. 2005 Dec 23;33(22):e187.

39.

Syk activation in dendritic cells is essential for airway hyperresponsiveness and inflammation.

Matsubara S, Koya T, Takeda K, Joetham A, Miyahara N, Pine P, Masuda ES, Swasey CH, Gelfand EW.

Am J Respir Cell Mol Biol. 2006 Apr;34(4):426-33. Epub 2005 Dec 9.

40.

Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsiveness.

Matsubara S, Li G, Takeda K, Loader JE, Pine P, Masuda ES, Miyahara N, Miyahara S, Lucas JJ, Dakhama A, Gelfand EW.

Am J Respir Crit Care Med. 2006 Jan 1;173(1):56-63. Epub 2005 Sep 28.

41.

Radical reactions of a stable N-heterocyclic germylene: EPR study and DFT calculation.

Tumanskii B, Pine P, Apeloig Y, Hill NJ, West R.

J Am Chem Soc. 2005 Jun 15;127(23):8248-9.

PMID:
15941234
42.

Medicaid spending and utilization for central nervous system drugs.

Baugh DK, Pine PL, Blackwell S, Ciborowski G.

Health Care Financ Rev. 2004 Fall;26(1):57-73.

43.

Determination of plasma and brain levels of isotretinoin in mice following single oral dose by high-performance liquid chromatography.

Yang Y, Faustino PJ, Pine PS, Davis H, Grunberg N, Phillips J, Lyon RC, Yu LX, Ciavarella AB, Del Grosso AV, Hanig JP.

J Pharm Biomed Anal. 2005 Feb 7;37(1):157-63.

PMID:
15664756
44.

Developmental neurotoxicity of ketamine: morphometric confirmation, exposure parameters, and multiple fluorescent labeling of apoptotic neurons.

Scallet AC, Schmued LC, Slikker W Jr, Grunberg N, Faustino PJ, Davis H, Lester D, Pine PS, Sistare F, Hanig JP.

Toxicol Sci. 2004 Oct;81(2):364-70. Epub 2004 Jul 14.

PMID:
15254342
45.

Medicaid prescription drug spending in the 1990s: a decade of change.

Baugh DK, Pine PL, Blackwell S, Ciborowski G.

Health Care Financ Rev. 2004 Spring;25(3):5-23.

46.

Radical reactions of a stable N-heterocyclic silylene: EPR study and DFT calculation.

Tumanskii B, Pine P, Apeloig Y, Hill NJ, West R.

J Am Chem Soc. 2004 Jun 30;126(25):7786-7.

PMID:
15212520
47.

Identification of platform-independent gene expression markers of cisplatin nephrotoxicity.

Thompson KL, Afshari CA, Amin RP, Bertram TA, Car B, Cunningham M, Kind C, Kramer JA, Lawton M, Mirsky M, Naciff JM, Oreffo V, Pine PS, Sistare FD.

Environ Health Perspect. 2004 Mar;112(4):488-94.

48.

Dye bias correction in dual-labeled cDNA microarray gene expression measurements.

Rosenzweig BA, Pine PS, Domon OE, Morris SM, Chen JJ, Sistare FD.

Environ Health Perspect. 2004 Mar;112(4):480-7.

49.

Virtual neuropathology: three-dimensional visualization of lesions due to toxic insult.

Lester DS, Pine PS, Delnomdedieu M, Johannessen JN, Johnson GA.

Toxicol Pathol. 2000 Jan-Feb;28(1):100-4.

PMID:
10668995
50.

Trends in Medicaid prescription drug utilization and payments, 1990-97.

Baugh DK, Pine PL, Blackwell S.

Health Care Financ Rev. 1999 Spring;20(3):79-105.

Supplemental Content

Support Center